PURPOSE. Retinal neovascularization (NV) is a major cause of vision loss in ischemia-induced retinopathy. Tumor necrosis factor (TNF)-like weak inducer of apoptosis (TWEAK) and its receptor, fibroblast growth factor inducible-14 (Fn14), have been implicated in angiogenesis, but their role in retinal diseases is unknown. The goal of this study was to investigate the role of TWEAK/Fn14 pathway in retinal NV.
R etinal neovascularization (NV) is a major cause of irreversible vision loss in ischemia-induced retinopathy such as retinopathy of prematurity, diabetes, and retinal vein occlusion. The standard options to treat retinal NV, include retinal laser photocoagulation, cryotherapy, and vitrectomy; however, they are destructive and the functional outcomes are often suboptimal. [1] [2] [3] In recent years, intravitreal injection of anti-VEGF agents shows promise to cause regression of the retinal NV, 4 but there are significant concerns such as systemic offtarget effects, short-lived effects, and potential neuronal and glial toxicity. [5] [6] [7] Severe side effects have also been reported when anti-VEGF agents were used in preterm infants to treat retinopathy of prematurity. 8 Thus, it is imperative to further understand mechanisms of NV in order to develop new therapeutic targets.
Tumor necrosis factor (TNF)-like weak inducer of apoptosis (TWEAK), a member of TNF family, is initially synthesized as a type II transmembrane protein that can be cleaved to a soluble factor with biological activity. 9, 10 Fibroblast growth factor inducible-14 (Fn14), the smallest member of the TNF receptor superfamily, has been recognized as TWEAK receptor. 11 The TWEAK/Fn14 pathway has been shown to play an essential role in the pathogenesis of stroke, kidney injury, muscle atrophy, and a number of inflammatory diseases. [12] [13] [14] It also has been implicated in angiogenesis by studies that have reported its role in endothelial cell migration, proliferation, and tube formation. [15] [16] [17] While in vivo studies have linked the TWEAK/Fn14 pathway to angiogenesis using the rodent corneal pocket assay model, 11, 18 the role of TWEAK/Fn14 pathway in retinal NV remains completely unknown.
METHODS

Treatment of Animals
All animal experiments were conducted in accordance with the ARVO Statement for the Use of Animals in Ophthalmic and Vision Research and were approved by the University of Texas Medical Branch (UTMB) Institutional Animal Care and Use Committee. Oxygen-induced retinopathy (OIR) was induced by maintaining C57BL/6J mice in 75% oxygen from postnatal day (P)7 to P12, followed by a return to room air (RA) from P12 to P17. 19, 20 Age-matched mice maintained in RA from birth to P17 served as RA control. To investigate the effect of hyperoxia treatment (HT), OIR mice were maintained in RA from P12 to P14 and then returned to 75% oxygen from P14 to P17. At the end of treatment, mice were euthanized and their eyes or retinas were prepared for morphology or molecular biology studies.
Intravitreal Injection
Mice were anesthetized by intraperitoneal injection of a mixture of ketamine hydrochloride (100 mg/kg) and xylazine hydrochloride (10 mg/kg). Intravitreal injections were performed as described previously. 20, 21 In brief, at P12, 0.5 lL PBS containing 2.5 lg soluble Fn14-Fc decoy receptor (R&D Systems, Minneapolis, MN) 13 or vehicle only was delivered to the vitreous with a 35-gauge needle mounted to a 10-ll NanoFil syringe (World Precision Instruments, Sarasota, FL). The tip of the needle was inserted under the guidance of a Leica Wild M650 dissecting microscope (Leica, Bannockburn, IL) through the dorsal limbus of the eye.
Immunostaining of Retinal Whole Mounts
After fixation in 4% paraformaldehyde, retinas were dissected from the choroid and sclera, blocked, and permeabilized in PBS containing 10% normal goat serum and 1% Triton X-100 for 30 minutes, and then incubated with Alexa Fluor 594-labeled isolectin B4 (Griffonia simplicifolia; 1:200; Invitrogen, Carlsbad, CA) overnight at 48C. For Fn14 expression, retinas were incubated with anti-Fn14 (1:200; Biolegend, San Diego, CA) and isolectin B4 overnight at 48C, which was followed by the incubation with Alexa Fluor 488-labeled goat anti-mouse secondary antibody (1:400; Invitrogen) for 4 hours at 48C. Next, retinas were washed with PBS, mounted with Vectashield mounting medium (Vector Laboratories, Burlingame, CA), and examined with an Olympus 1X71 fluorescence microscope (Olympus, Center Valley, PA) or confocal microscopy (Zeiss 510; Carl Zeiss, Thornwood, NY). Areas of vasoobliteration and retina NV were quantified using ImageJ software (National Institutes of Health, Bethesda, MD), as previously reported. 22 
Immunostaining of Retinal Sections
After fixation in 4% paraformaldehyde, retinas were equilibrated in 30% sucrose and embedded in optimal cutting temperature compound (Tissue Tek; Sakura Finetek, Torrance, CA). They were then frozen in liquid nitrogen and cut into 10lm sections. Retinal sections were placed on a glass slide, washed with PBS, and permeabilized with PBS containing 1% Triton X-100 for 30 minutes at room temperature before blocking with PBS containing 10% normal goat serum for 1 hour. Sections were incubated overnight at 48C with Alexa Fluor 594-labeled isolectin B4 (1:200; Invitrogen) and primary antibody against Fn14 (1:1000; Abcam, Cambridge, MA) or TWEAK (1:1000; Novus Biologicals, Littleton, CO) in PBS containing 3% normal goat serum. Next, sections were washed with PBS, incubated with Alexa Fluor 488-labeled goat antirabbit secondary antibody (1:400; Invitrogen) at room temperature for 1 hour, washed with PBS, mounted with mounting medium containing 4 0 ,6-diamidino-2-phenylindole (DAPI; Vector Laboratories), and examined with a fluorescence microscope (Olympus 1X71; Olympus).
Isolation of Retinal Vessels
Retinal vessels were isolated from other retinal cellular components as previously described. 20 Briefly, retinas were dissected and incubated in sterile water at 48C for 1 hour, and then incubated in 4 mL distilled water containing 500 U DNase I (Worthington Biochemical Corp., Lakewood, NJ) in a 60-mm dish for 10 minutes. During the latter incubation, the solution was gently and repeatedly pipetted onto the retinal tissue until the preparation became transparent. The retina was then transferred back to water and retinal vessels were separated from the remaining debris. The purity of the isolated vessels was assessed by microscopic examination after staining with periodic acid Schiff and hematoxylin.
RT-PCR Assay
Total RNA was isolated with an RNAqueous-4 PCR Kit (Invitrogen). Complementary DNA was produced by reverse transcription with Moloney Murine Leukemia Virus (M-MLV) reverse transcriptase (Invitrogen). Quantitative PCR (qPCR) was performed with StepOne PCR system (Invitrogen) using Power SYBR Green (Invitrogen). 21 The fold difference in various transcripts was calculated by the DDCT method using hypoxanthine guanine phosphoribosyltransferase (Hprt) or Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) as internal controls according to the Guide to Performing Relative Quantitation of Gene Expression Using Real-Time Quantitative PCR (Inivitrogen). Subsequently, a melting curve, constructed in the range of 608C to 958C, was used to evaluate the specificity of the amplification products. Primer sequences for mouse transcripts were as follows: Hprt For-5 0 -GAA AGA CTT GCT CGA GAT GTC ATG-3 0 ; Hprt Rev-5 0 -CAC ACA GAG GGC CAC AAT GT-3 0 ; Fn14 For-5 0 -CTG GTT TTG GCG CTG GTT-3 0 ; Fn14 Rev-5 0 -TCT CTC CGG CGG CAT CT-3 0 ; TWEAK For-5 0 -TGG GAA GAG ACC AAA ATC AAC A-3 0 ; and TWEAK Rev-5 0 -CCC AAT CTG GCG GTC GTA-3 0 . Primer sequences for human transcript were as follows: GAPDH For-5 0 -ATG GAA ATC CCA TCA CCA TCT T-3 0 ; GAPDH Rev-5 0 -CGC CCC ACT TGA TTT TGG-3 0 ; Fn14 For-5 0 -GCT CTG AGC CTG ACC TTC GT-3 0 ; Fn14 Rev-5 0 -TCC GCC GGT CTC CTC TAT G-3 0 ; TWEAK For-5 0 -GGA AAA CAC GGG CTC GAA-3 0 ; TWEAK Rev-5 0 -CCA GGT CGT GGA TGA ACT TCA-3 0 ; Bcl2 For-5 0 -GCT GGG AGA ACA GGG TAC GA-3 0 ; Bcl2 Rev-5 0 -TCT GCG ACA GCT TAT AAT GGA TGT- 
Western Blotting
Cells were lysed in a radioimmunoprecipitation assay lysis buffer (Millipore, Billerica, MA) supplemented with protease inhibitors (Roche Applied Science, Indianapolis, IN). The lysates were cleared of debris by centrifugation. Protein concentration in the lysates was determined by a bicinchoninic acid (BCA) assay (Pierce Biotechnology, Rockford, IL). The lysates were mixed with 43 SDS sample buffer and subjected to 10% SDS-PAGE, transferred onto a nitrocellulose membrane that was incubated with primary antibodies against Tubulin (1:10,000; Sigma-Aldrich, St. Louis, MO), HIF-1a (1:200; Santa Cruz Biotechnology, Dallas, TX), Fn14 (1:500) or Phospho-Akt (Ser473; #4058, 1:1000; Cell Signaling Technology, Danvers, MA) followed by horseradish peroxidase-conjugated secondary antibody. Immunoreactive proteins were detected using the enhanced chemiluminescence (ECL) system (GE Healthcare Bio-Sciences Corp., Piscataway, NJ).
Analysis of Transcription Factor Binding Sites
A 6-kb genomic sequence of human Fn14 gene (À4176 to 1802 bp) was aligned with the representative sequence from mouse Fn14 gene using rVista2.0 ([in the public domain] http://rvista. dcode.org). 23 Alignments were accomplished using the Mulan program, and conserved transcription factor binding sites were identified using the multiTF ([in the public domain] http:// mulan.dcode.org). In addition to the HIF-1a binding sequenc-es included in the multiTF program, the consensus core of hypoxia-responsive elements (RCGTG) 24 was used in the search of additional potential HIF-1a binding sites.
Construction of HIF-1a Adenovirus
Hypoxia inducible factor-1a adenovirus was made as described by Corley et al. 25 with modifications. 26 Human HIF-1a was cloned into the pAdTrack shuttle vector cytomegalovirus (CMV) promoter using KpnI and EcoRI restriction sites, and adenovirus plasmids containing green fluorescent protein (GFP) alone (AdGFP) and GFP together with HIF-1a (AdHIF-1a) were produced using the AdEasy XL System (Agilent Technologies, Santa Clara, CA). The AdGFP and AdHIF-1a were transfected into AD-293 cells and the viral particles were purified using the Adeno-X Virus Purification Kit according to manufacturer's instructions (Clontech Laboratories, Mountain View, CA).
Cell Culture
Primary human retinal microvascular endothelial cells (HRMECs) were purchased from Cell Systems (Kirkland, WA) 
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IOVS j February 2014 j Vol. 55 j No. 2 j 803 and cultured in medium constituted of 50% CSC Serum-Containing Medium (Cell Systems) and 50% EGM Endothelial Cell Medium (Lonza Walkersville, Inc., Walkersville, MD). Confluent HRMECs were infected with adenovirus carrying HIF-1a or GFP produced as described previously. 25, 26 The following day, cells were incubated overnight with serum free EGM. At 48 hours after infection, cells were stimulated with vehicle (PBS containing 0.1% BSA), VEGF (50 ng/mL; R&D systems), bFGF (20 ng/mL; PeproTech, Rocky Hill, NJ), or IL-1b (10 ng/mL; PeproTech) for 2 hours. Cells were then collected for analysis of the expression of HIF-1a and Fn14.
Analysis of Cell Survival
Human retinal microvascular endothelial cells were plated at a density of 4 3 10 4 cells/chamber in fibronectin-coated chambers of the eight-well electrode arrays (8W10E; Applied Biophysics, Inc., Troy, NY). The following day, cells were incubated overnight with serum free EGM and then treated with vehicle (serum free EGM) or TWEAK (200 ng/mL) for 4
days. The electrical cell-substrate impedance was measured at days 0, 1, 2, 3, and 4 after drug treatment using electrical cellsubstrate impedance sensing (ECIS; Applied Biophysics, Inc.). The basal level of impedance was measured in the absence of cells. Cells treated with vehicle at day 0 were used as reference. The percentage of normalized impedance was calculated as [Impedance treated À Impedance basal ]/[Impedance vehicle at day 0 À Impedance basal ] 3 100%. To examine cells at day 4 after treatment, cells were washed twice with PBS, fixed with 4% paraformaldehyde, and imaged by fluorescence microscope (Olympus 1X71) after mounted with mounting medium containing DAPI.
MTT
Human retinal microvascular endothelial cells were seeded at a density of 6 3 10 3 cells/well in collagen/fibronectin-coated 96well plates. The following day, cells were incubated with serum-free EGM overnight and then treated with vehicle (serum-free EGM) or TWEAK (200 ng/mL) for 4 days. After 
Statistical Analysis
Data are presented as mean 6 SEM. Statistical analysis was performed using SigmaStat 2.03 (SPSS, Inc., Chicago, IL). Group differences were evaluated with one-way ANOVA followed by post hoc Student's t-test using the Student-Newman-Keuls method. Results were considered significant at P less than 0.05.
RESULTS
Fn14 Is Upregulated in Ischemia-Induced Retinopathy
Studies were performed in a mouse model of OIR in which obliteration of the immature retinal vessels was induced by maintaining mice in 75% oxygen from P7 through P12. 19 Upon returning to RA, the avascular central retina became hypoxic, leading to upregulation of many angiogenic and inflammatory genes and, subsequently, retinal NV. 27 This model has been used extensively to study mechanisms and design strategies for blockade of pathologic NV in ischemia-induced retinopathy. [28] [29] [30] [31] To investigate the potential involvement of TWEAK/ Fn14 in NV, mRNA levels of Fn14 and TWEAK were measured from P12 to P17. Compared with the age-matched control mice kept in RA, Fn14 mRNA increased significantly in OIR retinas soon after relative hypoxia (P13) was initiated, and remained high (2.3-to 4.5-fold versus control) through P17 (Fig. 1A ).
During the same period, TWEAK mRNA was marginally decreased (less than 15%) in OIR (Fig. 1B) . These findings indicate that upregulation of Fn14 was associated with relative hypoxia and development of NV during ischemia-induced retinopathy.
Hyperoxia Treatment Normalizes Fn14 and TWEAK
To further explore the association of the Fn14/TWEAK pathway with OIR pathology, we determined mRNA levels of Fn14 and TWEAK at P17 in retinas from OIR mice treated with hyperoxia (75% oxygen, from P14-P17). This approach has been shown to eliminate retinal hypoxia, accelerate the process of revascularization and prevent development of pathologic NV in ischemia-induced retinopathy. 21 Our data showed that compared with OIR mice without treatment, hyperoxia treatment reduced Fn14 mRNA and increased TWEAK mRNA to RA levels (Fig. 2 ).
Fn14 Is Localized in NV Tufts in Ischemia-Induced Retinopathy
We next determined the retinal localization of Fn14 and TWEAK. Isolectin B4 was used as a marker for the retinal vasculature and DAPI was used to identify nuclei. In RA-control mice, the immunoreactivity of Fn14 was localized to inner nuclear layer (INL) and ganglion cell layer (GCL) with negligible expression in normal vessels (Fig. 3A) . In contrast, the OIR retina showed predominant localization of Fn14 in neovascular tufts, whereas the expression of Fn14 was less obvious in neuronal layers (Fig. 3A) . The immunoreactivity of TWEAK was diffused throughout the healthy retina, albeit more intense in the GCL, but it was increased predominantly in the neovascular tufts in OIR (Fig. 3B ). Fibroblast growth factor inducible-14 expression was also assessed by immunostaining whole-mount retinas, which showed the Fn14 protein was highly expressed in neovascular tufts in OIR rather than normal vessels in RA (Fig. 4 ).
Fn14 Is Upregulated in Retinal Vasculature in Ischemia-Induced Retinopathy
To evaluate whether Fn14 and TWEAK mRNA expressions were correlated with their increased immunoreactivity in the vasculature during OIR, retinal vessels were isolated and mRNA levels were determined by qPCR. Consistent with increased Fn14 immunoreactivity in neovascular tufts, Fn14 mRNA showed a 6.6-fold increase in OIR versus RA control (Fig.  5A) . In contrast, TWEAK mRNA was decreased by 46% in retinal vessels in OIR (Fig. 5B ).
The TWEAK/Fn14 Pathway Contributes to Retinal Neovascularization in Ischemia-Induced Retinopathy
The selective upregulation of Fn14 in retinal vasculature during OIR suggests a potential involvement of the TWEAK/ Fn14 pathway in retinal NV. To test this possibility, an Fn14-Fc decoy receptor was injected into the vitreous cavity of the OIR mice at P12 to block the interaction between Fn14 and TWEAK. 13 Compared with the OIR control group that received intravitreal injection of vehicle, blockade of the TWEAK/Fn14 pathway significantly reduced retinal NV by 45% (Figs. 6A, 6B ). While the retinal avascular area was reduced by 24%, it did not reach statistical significance (Figs.  6A, 6C) . These findings indicate that the TWEAK/Fn14 pathway plays a key role in the pathogenesis of ischemiainduced retinopathy. 
Blockade of the TWEAK/Fn14 Pathway Does not Alter VEGF Expression in Ischemia-Induced Retinopathy
Vascular endothelial growth factor is a potent angiogenic factor that plays a critical role in retinal NV in ischemia-induced retinopathy. 21, [32] [33] [34] The TWEAK/Fn14 pathway has been shown to promote ovarian cancer cell metastasis by upregulating VEGF expression. 35 To investigate whether the TWEAK/ Fn14 pathway contributes to retinal neovascularization by similar mechanism, the level of VEGF mRNA was analyzed after intravitreal injection of Fn14-Fc decoy receptor ( Fig. 7) . Vascular endothelial growth factor expression was unaffected by blocking the interaction between Fn14 and TWEAK, suggesting that the TWEAK/Fn14 pathway is involved in retinal NV via a mechanism independent of VEGF expression in ischemia-induced retinopathy.
Activation of the TWEAK/Fn14 Pathway Enhances Survival of Retinal Microvascular Endothelial Cells
Previous studies have consistently shown that the TWEAK/ Fn14 pathway induces angiogenic responses such as endothelial cell migration, proliferation, and tube formation. [15] [16] [17] However, it remains controversial whether this pathway is involved in endothelial cell survival. 15, 16 As enhanced endothelial survival is critical for the development of retinal NV given that endothelial cells in the NV tufts are sensitive to apoptotic stimuli compared with normal retinal vessels, 20 we determined the survival of HRMECs in serum-deprived medium when cells were treated with TWEAK. Cell density was determined by measurement of electrical cell-substrate impedance with an ECIS. The degree of impedance change can be determined by multiple factors, including cell density, barrier function, cell-cell interaction, and quality of interaction of cells with the electrodes. 36 However, there is a strong correlation between the fall of impedance and extent of cell death when cell loss is significant. 37 As shown in Figure 8A , there was no impedance change in vehicle-treated cells 24 hours after being placed in culture media containing no serum. From days 2 to 4, the impedance fell to 49%, 26% and 9% of the initial level, respectively, indicating significant and continuous loss of cells. In contrast, TWEAK treatment significantly reduced HRMEC death. The impedance was 2.3-and 4.2-fold of vehicle-treated cells at days 3 and 4, respectively. Correlated with the reduced fall of impedance, there were more cells preserved in the electrodes 4 days after TWEAK treatment compared with vehicle treatment (Fig. 8B) . The effect of TWEAK in HRMEC survival was further confirmed by the MTT assay that showed a 2-fold increase in the number of viable cells after TWEAK treatment (Fig. 8C) . These results suggest that TWEAK/Fn14 may modulate retinal NV by promoting survival of retinal microvascular endothelial cells.
The TWEAK/Fn14 Pathway Regulates the Expression of Anti-and Proapoptotic Molecules
The B-cell lymphoma-2 (Bcl2) family of proteins regulate both intrinsic and extrinsic mechanisms of apoptosis and are essential for cell survival. 38 This family of proteins can be divided into two groups that have opposite functions on cell survival. B-cell lymphoma-2, Bcl-xL, Bcl-w, Mcl-1, and Bfl-1 are antiapoptotic proteins, whereas Bax, Bak, and Bim are proapoptotic proteins. To examine molecular mechanisms underlying TWEAK/Fn14-promoted retinal endothelial cell (EC) survival, the expression of several anti-and proapoptotic molecules in the Bcl2 family was determined by qPCR. These studies showed that serum deprivation significantly induced the expression of pro-apoptotic molecule Bim, and TWEAK treatment blocked this effect (Fig. 9A ). In addition, TWEAK induced the expression of antiapoptotic molecule Bfl-1 and slightly increased the levels of other two antiapoptotic molecules, Mcl-1 and Bcl-w (Fig. 9B) . Neither serum deprivation nor TWEAK treatment significantly changed the levels of Bcl2, Bcl-xL, Bax, and Bak (Fig. 9 ). Akt phosphorylation, another pathway involved in cell survival, was assayed and no difference between vehicle and TWEAK treatment was observed (data not shown). These findings suggest that TWEAK/Fn14 promote retinal endothelial cell survival by simultaneously activating survival pathways and inhibiting apoptotic pathways in the Bcl2 family.
HIF-1a Is Implicated in Upregulation of Fn14
Given that upregulation of Fn14 was involved in retinal NV in ischemia-induced retinopathy, it would be important to understand potential mechanisms underlying Fn14 expression during OIR. The upregulation of Fn14 during OIR and its normalization by oxygen supplementation suggested that hypoxia-induced factors are involved in Fn14 expression. To investigate how hypoxia-induced factors regulate Fn14 expression in ischemia-induced retinopathy, rVISTA2.0 software was used to perform a comparative sequence analysis of mouse and human genome and predict transcription factor binding sites in a 6-kb region of Fn14 gene. This analysis was based on the hypothesis that regulatory modules are under positive selection during evolution and are often conserved between species. 23 This approach has dramatically enhanced prediction accuracy compared with the analysis based only on the short sequence of transcription factor binding sites. 23 Our analysis revealed several conserved clusters in the noncoding DNA regions between human and mouse Fn14 genes (upper panel of Fig. 10 ). Within these clusters, there were 395 multiconserved transcription factor binding sites, including binding sites for nuclear factor-kappa B (NF-jB) that is known to regulate Fn14 transcription. 39 Among these transcription factor binding sites, there were 11 binding sites for HIF-1a (lower panel of Fig. 10 ). Since HIF-1a is known to play a pivotal role in hypoxia-induced responses, our analysis suggested that HIF-1a is a potential transcription factor involved in Fn14 expression during hypoxia.
To test this possibility, HIF-1a was introduced into HRMECs by adenovirus-mediated gene delivery and the level of Fn14 mRNA was analyzed. Compared with cells infected with adenovirus carrying GFP (AdGFP, control), the level of HIF-1a was high in cells infected with adenovirus carrying HIF-1a (AdHIF-1a; Fig. 11A ). Associated with increase in HIF-1a, the Fn14 mRNA level was significantly increased by 123% (Fig.  11B ). Consistently Fn14 protein was also significantly induced by HIF-1a (Fig. 11C) .
Given that levels of proangiogenic and proinflammatory cytokines, including VEGF, bFGF, or IL-1b are increased in ischemia-induced retinopathy and these molecules have been shown to induce Fn14 expression in other cells, 15, 21, 40, 41 it is possible that these cytokines also contribute to Fn14 upregulation in hypoxic retinas. To test this possibility, HRMECs were stimulated with VEGF, bFGF, or IL-1b in the presence or absence of HIF-1a. Although VEGF treatment induced 52% upregulation of Fn14 mRNA and had an additive effect with HIF-1a, bFGF and IL-1b did not induce upregulation of Fn14 in HRMECs and did not affect HIF-1a-induced Fn14 expression ( Fig. 11D) . Taken together, these results indicate that HIF-1a is likely involved in Fn14 expression and may work together with other cytokines to induce Fn14 expression in retinal endothelial cells during ischemia-induced retinopathy.
DISCUSSION
Retinal NV occurs after a period of ischemia due to the cessation of retinal vascular development, vessel regression, or occlusion. It can lead to vitreous hemorrhage, epiretinal or subretinal fibrosis, and tractional retinal detachment, resulting in profound irreversible vision loss. Laser photocoagulation is the common therapy for retinal NV; however, this method destroys retinal neurons and has significant side effects, including loss of visual field, reduced visual acuity, and impaired night vision. 4, 42 Anti-VEGF agents are now in widespread use for treatment of the subretinal NV associated with AMD. In ischemia-induced retinopathy, anti-VEGF drugs show promise, but issues such as efficacy, impairment of revascularization, and the long-term safety of VEGF antagonism have emerged as significant concerns for anti-VEGF therapy. [4] [5] [6] [7] 21 In this study, we provide the first evidence that the TWEAK/Fn14 pathway is prominently upregulated in retina during ischemia-induced retinopathy and blockade of the TWEAK/Fn14 pathway significantly reduces the extent of retinal NV. Unlike VEGF trap (VEGFR1-Fc decoy receptor), which reduces retinal NV but blocks retinal revascularization and increases avascular area, 21 the Fn14-Fc decoy receptor did not prevent retinal revascularization and the avascular area was actually slightly reduced. Considering the limitations of photocoagulation and anti-VEGF therapy, blocking TWEAK/ Fn14 pathway may provide an alternative therapeutic approach for preventing vision loss due to retinal NV in ischemiainduced retinopathy.
The TWEAK/Fn14 pathway is involved in various processes such as proinflammatory response, cell growth, cell survival, and cell death dependent on the cellular context. 43 It has been reported to be a key mediator in kidney injury, neuronal damage, and muscle atrophy. [12] [13] [14] Although the angiogenic function of this pathway was recognized soon after TWEAK was identified, 18 its role in physiological or pathologic angiogenesis in diseases has not been explored. Here, we found that Fn14 expression was upregulated at the beginning of the relative hypoxia period, prior to the appearance of NV tufts, and remained high throughout the period of NV formation during ischemia-induced retinopathy. Concurrently, the immunoreactivity of Fn14 and TWEAK shifted from neuronal layers in the healthy retina to neovascular tufts in OIR. This shift suggests the involvement of the TWEAK/Fn14 pathway in the formation and maintenance of ischemiainduced pathologic retinal angiogenesis. This possibility was supported by our finding that retinal NV was significantly reduced by blocking the TWEAK/Fn14 pathway. At present, it is unknown how TWEAK/Fn14 is involved in retinal NV. The selective upregulation of Fn14 in the NV tufts may highly sensitize endothelial cells to TWEAK, and therefore initiate angiogenesis processes such as cell proliferation, migration, and tube formation during retinal ischemia. [15] [16] [17] Moreover, our data indicate that activation of TWEAK/Fn14 pathway promoted HRMEC survival in a process that may involve TWEAK/Fn14-induced expression of survival molecules and inhibition of apoptotic molecules in the Bcl2 family. This property is important for the process of retinal NV, as neovascular tufts, unlike mature vessels, lack proper pericyte coating and interaction with glia, and are therefore sensitive to apoptotic signals. 20 Unlike previous studies that induced endothelial cell death by removing growth factors, 15, 16 we included bovine brain extract in the medium to mimic the in vivo condition in which endothelial cells are exposed to multiple survival cytokines secreted from neuronal tissue. The strikingly enhanced HRMEC survival by TWEAK treatment in our study highlights the role of TWEAK/Fn14 as an independent survival factor during NV. The precise mechanisms by which TWEAK/Fn14 regulates expression of Bcl2 family genes remain to be elucidated. Presumably, Fn14, after engaged by TWEAK, forms a trimmer that recruits TNFR-associated factor (TRAF) and induces rapid activation of canonical NF-jB followed by prolonged activation of noncanonical NF-jB. 44 Nuclear factor-jB then binds to the transcription regulator regions of Bcl2 family genes and regulates their transcription. 45, 46 In addition to the direct angiogenic impact on endothelial cells, the development of retinal NV depends on multiple other factors including upregulation of angiogenic factors, inflammation, and breakdown of internal limiting membrane. Our data indicate that VEGF is not a downstream mediator of TWEAK/Fn14-modulated retinal NV in the OIR model. However, TWEAK/Fn14 can induce expression of other angiogenic and inflammatory factors such as IL-6 and IL-8. 47 Tumor necrosis factor-like weak inducer of apoptosis/Fn14 pathway can also promote production of matrix metalloproteinase proteins, which may facilitate the breakdown of the internal limiting membrane. 48, 49 Further studies are required to explore the precise mechanisms of TWEAK/Fn14-induced retinal NV.
Fibroblast growth factor inducible-14 is normally expressed at low level under physiological conditions. Its expression is upregulated during tissue injury or diseases probably due to increases in growth factors and/or inflammatory factors under these conditions. 43 The highly inducible pattern of Fn14 expression is well conserved between mouse and human, suggesting this pathway is evolutionarily conserved. 43 Nevertheless little is known about mechanisms underlying regulation of Fn14 expression. To our knowledge, NF-jB is the only transcription factor that has been identified to induce Fn14 upregulation during inflammation. 39 In the current study, we provide new evidence that Fn14 expression was upregulated during the relative hypoxia period and was normalized with hyperoxia, suggesting hypoxia responsive factors are involved in Fn14 expression. With comparison analysis, we identified 11 predicted HIF-1a binding sites, which are conserved between the mouse and human gene. Our data that HIF-1a induces Fn14 expression in HRMECs support the hypothesis that Fn14 expression is hypoxia driven and HIF-1a is likely implicated in this process. This observation is different from the report by Vendrell et al, 50 in which upregulation of Fn14 expression in adipocytes and macrophages is induced by inflammatory cytokines, but not by hypoxia. Therefore HIF-1a-induced Fn14 expression is dependent on cellular contexts such as coactivators, cell-specific DNA methylation patterns, and post translational histone modifications in specific cell types. 51 Future studies that would include reporter gene assay, gel electrophoresis mobility shift assay, chromatin immunoprecipitation, histone acetylation/methylation analysis, and DNA methylation analysis are needed to identify HIF-1a binding sites in the Fn14 transcriptional regulation region, elucidate coactivators and determine the chromatin-based mechanisms in order to better understand the mechanisms underlying hypoxia-induced Fn14 expression in specific cell types. Although we show that HIF-1a is likely involved in Fn14 expression, other molecules produced in hypoxic retina, such as VEGF and IL-6, may further boost HIF-1a-induced Fn14 expression by activating other transcription regulatory elements.
In contrast to Fn14 expression, the TWEAK mRNA was downregulated in the retina and retinal vasculature during ischemia-induced retinopathy. However, the magnitude of Fn14 upregulation was higher than the magnitude of TWEAK downregulation; in other words, the ratio of Fn14 to TWEAK increased in hypoxic retina. We postulate that a high Fn14/ TWEAK ratio may offer selective activation of endothelial cells that show higher Fn14 upregulation. This notion is supported by our observation that the immunoreactivity of TWEAK was redistributed from neuronal layers in normal retina to the NV tufts during ischemia-induced retinopathy. Similar phenomenon of high receptor/ligand ratio as an activation mechanism has been previously described; for example, it has been shown that high ratio of Eph receptor to its ligand, ephrin, facilitates tumorogenesis. 52, 53 In summary, our data provide the first evidence that TWEAK/Fn14 pathway is activated and involved in pathologic retinal NV during ischemia-induced retinopathy. Given that angiogenesis is involved in other diseases such as tumors, limb ischemia, and neovascular AMD, this novel finding would encourage further exploration of the role of TWEAK/Fn14 in the pathogenesis of these diseases.
